Discover
NKTX
Nkarta, Inc.
3.19
2 x 2.34
1 x 3.87
bid
ask
+
0.33
11.75%
01:19 PM
timesize
| Ytd | 72.16% | |
| 1y | 83.05% |
2.82
day range
3.27
1.68
52 week range
3.65
| Open | 2.87 | Prev Close | 2.85 | Low | 2.82 | High | 3.27 | Mkt Cap | 227.80M |
| Vol | 892.30K | Avg Vol | 772.12K | EPS | -1.35 | P/E | N/A | Forward P/E | -1.42 |
| Beta | 0.87 | Short Ratio | 5.44 | Inst. Own | 99.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 2.89 | 200-d Avg | 2.33 | 1yr Est | 15.83 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.37 | -0.39 | -0.02 | -5.41% |
| 2024-08-13 | 2024-06 | -0.49 | -0.34 | 0.15 | 30.61% |
| 2024-08-13 | 2024-06 | -0.49 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.56 | -0.58 | -0.02 | -3.57% |
| 2024-05-09 | 2024-03 | -0.56 | N/A | N/A | N/A |
| 2024-03-21 | 2023-12 | -0.62 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-21 | Mizuho | Upgrade | Outperform | Outperform |
| 2024-11-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-08 | Needham | Upgrade | Buy | Buy |
| 2024-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-14 | Needham | Upgrade | Buy | Buy |
| 2024-08-14 | Raymond James | Upgrade | Outperform | Strong Buy |
Profile
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-17 | BRANDENBERGER RALPH ERIK | Chief Technology Officer | 79.74K | Sale |
| 2024-03-26 | GEORGE SIMEON J. | Director | 0.00 | Purchase |
| 2024-07-15 | HAGER ALICIA J | Officer | 103.82K | Sale |
| 2024-06-17 | HASTINGS PAUL J | Chief Executive Officer | 240.74K | Sale |
| 2024-01-03 | LEVIN ALYSSA | Chief Financial Officer | 56.00K | Stock Award(Grant) |
| 2023-06-19 | MAHMOOD NADIR AHMEDUDDIN | Chief Financial Officer | 85.78K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | RA Capital Management, L.P. | 10.81M | 27.01M | 15.31% |
| 2024-09-29 | Commodore Capital Lp | 4.66M | 11.66M | 6.61% |
| 2024-09-29 | Blackrock Inc. | 4.22M | 10.56M | 5.98% |
| 2024-09-29 | Boxer Capital, LLC | 4.03M | 10.07M | 5.71% |
| 2024-09-29 | Samsara BioCapital, LLC | 3.77M | 9.42M | 5.34% |
| 2024-09-29 | Adage Capital Partners GP L.L.C. | 3.60M | 9.00M | 5.10% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.82M | 4.55M | 2.58% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.37M | 3.43M | 1.95% |
| 2024-09-29 | Wasatch Ultra Growth Fund | 1.02M | 2.56M | 1.45% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 704.88K | 1.76M | 1.00% |
| 2024-09-29 | Wasatch Microcap Fund | 668.36K | 1.67M | 0.95% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 542.22K | 1.36M | 0.77% |